Adjunctive High-dose Intravenous Immunoglobulin Treatment for Resistant Atopic Dermatitis: Efficacy and Effects on Intracellular Cytokine Levels and CD4 Counts

Acta Dermato-Venereologica

Volumn 83, Issue 6, 2003, Pages 433-437

  Jolles, Stephen ^a,b   Sewell, Carrock ^b   Webster, David ^b   Ryan, Annie ^b   Heelan, Bridget ^b   Waite, Annie ^b   Rustin, Malcolm ^b  

^a NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Atopic dermatitis; Intracellular cytokines; Intravenous immunoglobulin

Indexed keywords

AZATHIOPRINE; CD4 ANTIGEN; CD69 ANTIGEN; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOLOGICAL ADJUVANT; PARACETAMOL; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; ATOPIC DERMATITIS; CELL LEVEL; CLINICAL ARTICLE; CYTOKINE RELEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REDUCTION; T LYMPHOCYTE;

ADOLESCENT; ADULT; CD4 LYMPHOCYTE COUNT; CYTOKINES; DERMATITIS, ATOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0345258012     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/00015550310020549     Document Type: Article

References (21)

1. Jolles S, Hughes J, Rustin M. The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. Br J Dermatol 2000; 142: 551-554.
2. Gelfand EW, Landwehr LP, Esterl B, Mazer B. Intravenous immune globulin: an alternative therapy in steroid-dependent allergic diseases. Clin Exp Immunol 1996; 104 Suppl. 1: 61-66.
3. Kimata H. High-dose gammaglobulin treatment for atopic dermatitis. Arch Dis Child 1994; 70: 335-336.
4. Wakim M, Alazard M, Yajima A, Speights D, Saxon A, Stiehm ER. High-dose intravenous immunoglobulin in atopic dermatitis and hyper-IgE syndrome. Ann Allergy Asthma Immunol 1998; 81: 153-158.
5. Weiss SJ, Schuval SJ, Bonagura VR. Eczema and thrombocytopenia in an 8-month-old infant boy. Ann Allergy Asthma Immunol 1997; 78: 179-182.
6. Huang JL, Lee WY, Chen LC, Kuo ML, Hsieh KH. Changes of serum levels of interleukin-2, intercellular adhesion molecule-1, endothelial leukocyte adhesion molecule-1 and Th1 and Th2 cell in severe atopic dermatitis after intravenous immunoglobulin therapy. Ann Allergy Asthma Immunol 2000; 84: 345-352.
7. Paul C, Dubertret L. A randomized controlled evaluator-blinded trial of intravenous immunoglobulin in adults with severe atopic dermatitis. Br J Dermatol 2002; 147: 518-522.
8. Sewell WA, Jolles S. Immunomodulatory action of intravenous immunoglobulin. Immunology 2002; 107: 387-393.
9. Shapiro S, Shoenfeld Y, Gilburd B, Sobel E, Lahat N. Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 2002; 95: 2032-2037.
10. Spahn JD, Leung DY, Chan MT, Szefler SJ, Gelfand EW. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin. J Allergy Clin Immunol 1999; 103: 421-426.
11. Vassilev TL, Kazatchkine MD, Van Huyen JP, Mekrache M, Bonnin E, Mani JC, et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 1999; 93: 3624-3631.
12. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001; 291: 484-486.
13. Bayry J, Lacroix-Desmazes S, Carbonneil C, Misra N, Donkova V, Pashov A, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003; 101: 758-765.
14. Jolles S, Hughes J, Whittaker S. Dermatological uses of high-dose intravenous immunoglobulin. Arch Dermatol 1998; 134: 80-86.
15. Hanifin J, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol Suppl. 1980; 114: 146-148.
16. Rajka G, Langeland T. Grading of the severity of atopic dermatitis. Acta Derm Venereol Suppl 1989; 144: 13-14.
17. Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 2001; 10: 11-18.
18. Sewell WA, North ME, Webster AD, Farrant J. Determination of intracellular cytokines by flow-cytometry following whole-blood culture. J Immunol Methods 1997; 209: 67-74.
19. Sewell WA, North ME, Cambronero R, Webster AD, Farrant J. In vivo modulation of cytokine synthesis by intravenous immunoglobulin. Clin Exp Immunol 1999; 116: 509-515.
20. Noh G, Lee KY. Intravenous immune globulin (i.v. IG) therapy in steroid-resistant atopic dermatitis. J Korean Med Sci 1999; 14: 63-68.
21. Sewell WA, Brennan VM, Donaghy M, Chapel HM. The use of self infused intravenous immunoglobulin home therapy in the treatment of acquired chronic demyelinating neuropathies. J Neurol Neurosurg Psychiatry 1997; 63: 106-109.